WO1998032744A1 - Process for manufacturing fluconazole - Google Patents
Process for manufacturing fluconazole Download PDFInfo
- Publication number
- WO1998032744A1 WO1998032744A1 PCT/KR1998/000018 KR9800018W WO9832744A1 WO 1998032744 A1 WO1998032744 A1 WO 1998032744A1 KR 9800018 W KR9800018 W KR 9800018W WO 9832744 A1 WO9832744 A1 WO 9832744A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- fluconazole
- reaction
- compound
- monohydrate
- Prior art date
Links
- 0 *[n]1ncnc1 Chemical compound *[n]1ncnc1 0.000 description 1
- XCHRPVARHBCFMJ-UHFFFAOYSA-N O=C(C[n]1ncnc1)c(c(F)c1)ccc1F Chemical compound O=C(C[n]1ncnc1)c(c(F)c1)ccc1F XCHRPVARHBCFMJ-UHFFFAOYSA-N 0.000 description 1
- GSGRUEAYRZZEAC-UHFFFAOYSA-N O=S1(OCC(C[n]2ncnc2)(c(c(F)c2)ccc2F)[O-]1)=O Chemical compound O=S1(OCC(C[n]2ncnc2)(c(c(F)c2)ccc2F)[O-]1)=O GSGRUEAYRZZEAC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the invention herein relates to a process for the manufacture of fluconazole, or more particularly, to the process for the manufacture of fluconazole of Formula 1 having superior antifungal activity with a high yield and purity, and its pharmaceutically acceptable salt or hydrate, wherein one-pot reaction is utilized under a mild reaction condition and short reaction time by means of using three compounds expressed by the following formula 2, 3, and 4, respectively, in the presence of a base.
- Fluconazole expressed by Formula 1, was developed in 1982 [U.K. Patent Application No. 2078719 (1982); Korean Patent Application No. 82-2493] and has been widely used as effective antifungal agents in the clinical field.
- U. K. Patent Application No. 2270521 (1993) discloses a method of synthesizing fluconazole monohydrate from fluconazole anhydrous. According to the U.K. patent, the water content of fluconazole anhydrous was 0.1% while that of fluconazole monohydrate was 5.6%.
- Korean Patent Application No. 82-2493 discloses a method of manufacturing fluconazole of Formula 1 based on the process as shown in the following Scheme 1.
- the compound of Formula 5 is reacted with the compound of Formula 6, followed by an intermediate expressed by Formula 7, and fluconazole is synthesized having its production yield of 60.5%.
- the production yield from the compound expressed by Formula 2 is not more than 22% (Korea Patent Application No. 82-2493).
- the actual total yield based on this method is as low as 13.3%.
- a corrosive acid with toxicity and sodium nitrite must be employed.
- the de-amination under such conditions must be performed at an extremely low temperature, and if the adjustment to such temperature fails, there is a risk of explosion. Therefore, Scheme 2 does not seem to be adequate for the large-scale industrial production.
- the total yield based on the scheme 3 also proves not to be in a satisfactory level as it is only 27%.
- the reaction must be performed at a high temperature (140-160 ° C), and bromination intended for manufacturing the compound of Formula 10 is extremely dangerous as a radical reaction, and some reagents used for this reaction is quite toxic, thus making it difficult to apply the scheme 3 to the industrial purpose.
- the Spanish Patent Nos. 8604939, 8605753 and 2049663 disclose one-step manufacturing process of synthesizing a compound expressed by Formula 1, as shown in the following scheme 5.
- X is OCH3, OCH2CH3 or Cl; M is MgBr or Li.
- the target compound was synthesized with a relatively high yield (45-85%). Nevertheless, l-(halomethyl)-l,2,4-triazole used for the synthesis of the compound of Formula 16 is an expensive reagent, the synthesis of such compound is not easy, and its yield is quite low. Since the Grignard reagent or the reagent containing lithium used for this reaction has an explosively high reactivity and is very sensitive to water and air, the reaction must be performed in the anhydrous condition. Hence, the application of the scheme 5 is extremely difficult in the commercial production.
- the scheme 6 has a disadvantage in that since the reactants are subjected to heterogeneous reaction, the reaction time becomes extended up to 24 hours, and the separation and purification of the by-products are not easily made available.
- the silica gel column is not suitable for the industrial production.
- the relative area ratio of fluconazole (RT 4.65) within the reacting solution was 23% while the majority of byproducts occupied 73% in the reacting solution.
- the inventor et al. have conducted intensive studies covering the method of synthesizing fluconazole expressed by Formula 1 in an easy manner with a high yield and purity. Therefore, the invention herein has been devised using water or a co-solvent consisting of water and an organic solvent, so as to ensure the homogeneous reaction where reagents are completely dissolved under a mild condition and with easily handled reagents.
- the objective of said invention is to provide a process of manufacturing fluconazole expressed by Formula 1 in an easy manner with a high yield and purity via the reaction in which the completely dissolved reagents are in homogeneous state.
- Fig. la shows the results of the HPLC analysis of the reaction solution prior to the addition of the compound expressed by Formula 3 from the conventional process of manufacturing fluconazole based upon in-situ reaction.
- Fig. lb shows the results of the HPLC analysis of the reaction solution which has been in a reaction for one hour with the addition of the compound expressed by Formula 3 from the conventional process of manufacturing fluconazole based upon in- situ reaction.
- Fig. 2 shows the results of the HPLC analysis of the one-pot reaction of said invention.
- Fig. 3 show the results of the HPLC analysis of the reaction solution according to the referential example (J. Heterocyclic Chem., 30, 1405, 1993).
- the invention herein relates to a process of manufacturing fluconazole expressed by Formula 1 using two compounds of Formula 3 and 4 respectively, and the compound of Formula 2 as a starting material, wherein two compounds of the Formula 3 and 4 are added to the compound of Formula 2 for one-pot reaction.
- the reaction is carried out by selecting water, or an organic solvent which may be mixed with water and a water-mixed co-solvent.
- the reaction is carried out by selecting water, or an organic solvent which may be mixed with water and a water-mixed co-solvent, thus allowing the reaction reagents to be completely dissolved.
- said invention has several advantages in that a) compared with the reaction performed in the presence of a conventional organic solvent such as t-butanol (J. Heterocyclic Chem., 30, 1405, 1993), its production yield increases from 38% to 70% or more, b) reaction time is shortened to one or two hours from 24 hours, c) reduction in the by-products in the reaction may facilitate separation and purification of the target product.
- the reactants used during the process of manufacturing fluconazole according to said invention is the same as that used in the Korea Patent Application No. 82-2493.
- said invention is entirely different from the later in terms of order and methods in adding the reactants.
- the invention herein generates new reaction conditions within the system, and as a result, it was confirmed that some unexpected effects such as reaction yield, etc. had occurred. Since said invention is different from the conventional methods in terms of the reaction method, it is assumed that each of the different reaction mechanism may contribute much to the remarkable synergic effect in the production yield.
- the manufacturing process under said invention (one-pot reaction), and in situ reaction mechanism based on the Korea Patent Application No. 82-2493 may be illustrated in the following scheme 7.
- the manufacturing process under the Korea Patent Application No. 82-2493 is characterized in that epoxide expressed by Formula 5, so generated as an intermediate, is separately isolated, and then the above compound is reacted with the compound of Formula 3 to synthesize fluconazole of Formula 1.
- This process corresponds to the mechanism where the compound of Formula 3 is subjected to in-situ reaction after the starting material is completely converted to the intermediate compound.
- the in-situ reaction has been reported to have an improved production yield.
- the in-situ reaction is actually carried out in such a manner that the first-step process is internally complete without the second-step reaction or intermediate-separation process.
- the second-step process is performed.
- Such process appears be a first-step process, but it includes second-step process in terms of reaction mechanism.
- the manufacturing process of the invention is basically different from that of the in-situ reaction since its first-step reaction is carried out with the addition of reaction materials at the initial stage irrespective of any generation of intermediates (Formula 5 and 17).
- the following tests have been performed.
- RT 1.4 (18.7%, compound of Formula 4), RT 3.02 (14%), regio-isomer of fluconazole), RT 3.91 (4.0%), compound of Formula 18), RT 4.56 (52%>, compound of Formula 1), RT 6.32 (7.3%o, unknown compound),
- the in-situ reaction had high production rates of by-products expressed by Formula 18 and unknown compounds instead of fluconazole, and the generation yield of fluconazole based on quantitative analysis was 33.8%.
- its main product is fluconazole of Formula 1 , the target compound, and the production yield of fluconazole based on quantitative analysis was 88%.
- the reaction between sulfoxonium ylide and carbonyl group is a reversible reaction, and its reaction rate has been reported to be very fast.
- the nucleophilic substitution between the compound of Formula 17 and nucleophiles is an irreversible reaction, and its reaction rate has been reported to be very slow as compared to that in the first-step reaction. Therefore, the rate determining step of this reaction is a nucleophilic substitution step. If the compound of Formula 17 is stable enough to be present during the reaction time with other nucleophiles, the relative ratio of the final product is determined by the nucleophilic substitution rate.
- the relative production ratio of a product from the rate determining step is determined by the reaction rate. Since the reaction rate via pathway 1 is relatively faster than that of the pathway 2, the compound of Formula 1 is mainly generated via pathway 1.
- the main reaction mechanism according to said invention is assumed to be based on the nucleophilic substitution between the two compounds expressed by Formula 17 and 3, respectively while the mechanism via the compound of Formula 5 is assumed to be an additional reaction. Further, the yields under the process as set forth in Bauer et al. [J. Heterocyclic
- a solvent which will sufficiently dissolve the compound of Formula 3 is needed.
- the homogeneous reaction system in which the compound of Formula 3 is completely dissolved, is used.
- water or a co-solvent consisting of water and organic solvent is used as a reaction solvent so as to effectuate the homogeneous reaction.
- an organic solvent which may be mixed with water, is employed.
- the manufacturing process under said invention it is preferable to use 1 g of the compound of Formula 2 in 5 - 10 ml and the reaction temperature in the range of 50 ° C and the reflux temperature.
- the reagent used for the manufacturing process of said invention it is preferred that each of two compounds expressed by Formula 3 and 4 respectively, be used in the equivalent ratio of 1 to 2, in proportion to the compound expressed by Formula 2.
- a common type of base may be used.
- potassium hydroxide and sodium hydroxide as a base. It is preferred that its amount be in the equivalent ratio of 2 to 4, in proportion to the compound of Formula 2.
- fluconazole is prepared in the form of monohydrate.
- the invention herein includes a process of manufacturing fluconazole expressed by Formula 1 , its pharmaceutically acceptable salt or hydrate.
- the materials commonly available may be applicable in the manufacture of the pharmaceutically acceptable salt of fluconazole, and its manufacture may be easily made available by the common method.
- fluconazole monohydrate is dissolved in the alcohol solvent at a hot temperature (40 ° C to reflux temperature) and cooled at below 5 ° C .
- fluconazole anhydrous was prepared either by precipitating and filtering fluconazole anhydrous or by removing the solvent under vacuum.
- This aqueous solution was extracted with methylene chloride (100ml) and washed with saturated sodium bicarbonate solution (50ml), Then this methylene chloride layer was extracted with 5% HC1 solution (50ml). The aqueous solution, so extracted, was washed with ethyl acetate (50ml), and with the addition of activated carbon (l.Og), the reaction solution was stirred for 30 minutes and filtered. The filtrate was cooled at below 5 ° C , neutralized with ammonia water and stirred for 1 hour. The precipitate ' was filtered and washed with water. A white solid, so formed by filtering, was dried for 5 hours under vacuum.
- Example 7 Preparation of fluconazole anhydrous Fluconazole monohydrate (5.0g, 15.42mmol), so prepared from the example 1, was completely dissolved in a hot isopropanol (25ml), cooled again at below 5 °C and stirred for 1 hour. The precipitate, so generated, was filtered and dried under reduced pressure. The above solid was confirmed to be fluconazole anhydrous (4.5g, yield: 95%) and it coincided with those materials prepared by the Korean Patent Application No. 82- 2493, and U.K. Patent Application No. 2270521 (1993) in terms of water content (0.1% or less).
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98902274A EP1001947A1 (en) | 1997-01-29 | 1998-01-24 | Process for manufacturing fluconazole |
SK1332-98A SK133298A3 (en) | 1997-01-29 | 1998-01-24 | Process for manufacturing fluconazole |
HU0000726A HUP0000726A3 (en) | 1997-01-29 | 1998-01-24 | Process for manufacturing fluconazole |
AU58823/98A AU5882398A (en) | 1997-01-29 | 1998-01-24 | Process for manufacturing fluconazole |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1997/2700 | 1997-01-29 | ||
KR1019970002700A KR100194945B1 (en) | 1997-01-29 | 1997-01-29 | Method for producing fluconazole |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998032744A1 true WO1998032744A1 (en) | 1998-07-30 |
Family
ID=19495904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR1998/000018 WO1998032744A1 (en) | 1997-01-29 | 1998-01-24 | Process for manufacturing fluconazole |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1001947A1 (en) |
KR (1) | KR100194945B1 (en) |
AU (1) | AU5882398A (en) |
CZ (1) | CZ308398A3 (en) |
HU (1) | HUP0000726A3 (en) |
PL (1) | PL329117A1 (en) |
SK (1) | SK133298A3 (en) |
WO (1) | WO1998032744A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100341688B1 (en) * | 1999-04-16 | 2002-06-24 | 윤재승 | Process for the Preparation of Fluconazole |
WO2002076955A1 (en) * | 2001-03-23 | 2002-10-03 | Richter Gedeon Vegyeszéti Gyár Rt. | Process for preparing fluconazole and its crystal modifications |
WO2015058272A1 (en) * | 2013-10-23 | 2015-04-30 | Iharabras S.A. Indústrias Químicas | Process for selectively preparing (1h-1,2,4-triazol-1-yl)alkanols, hydrazinyl alkanol compound produced by said process and use thereof |
CN106749055A (en) * | 2016-12-19 | 2017-05-31 | 苏州天马精细化学品股份有限公司 | A kind of preparation method of Fluconazole |
JP2018533635A (en) * | 2015-11-17 | 2018-11-15 | ダウ アグロサイエンシィズ エルエルシー | 4-((6- (2- (2,4-Difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propyl) pyridine -3-yl) oxy) benzonitrile and method of preparation |
JP2018538366A (en) * | 2015-11-17 | 2018-12-27 | ダウ アグロサイエンシィズ エルエルシー | 4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propyl) pyridine-3 -Yl) oxy) benzonitrile and preparation method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0069442A1 (en) * | 1981-06-06 | 1983-01-12 | Pfizer Limited | Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them |
WO1995007895A1 (en) * | 1993-09-13 | 1995-03-23 | Acic (Canada) Inc. | Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole |
WO1996020181A1 (en) * | 1994-12-23 | 1996-07-04 | Acic (Canada) Inc. | Commercial process for the manufacture of fluconazole and intermediates useful in the manufacture thereof |
-
1997
- 1997-01-29 KR KR1019970002700A patent/KR100194945B1/en not_active IP Right Cessation
-
1998
- 1998-01-24 WO PCT/KR1998/000018 patent/WO1998032744A1/en not_active Application Discontinuation
- 1998-01-24 AU AU58823/98A patent/AU5882398A/en not_active Abandoned
- 1998-01-24 SK SK1332-98A patent/SK133298A3/en unknown
- 1998-01-24 EP EP98902274A patent/EP1001947A1/en not_active Withdrawn
- 1998-01-24 HU HU0000726A patent/HUP0000726A3/en unknown
- 1998-01-24 CZ CZ983083A patent/CZ308398A3/en unknown
- 1998-01-24 PL PL98329117A patent/PL329117A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0069442A1 (en) * | 1981-06-06 | 1983-01-12 | Pfizer Limited | Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them |
WO1995007895A1 (en) * | 1993-09-13 | 1995-03-23 | Acic (Canada) Inc. | Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole |
US5508423A (en) * | 1993-09-13 | 1996-04-16 | Acic (Canada) Inc. | Methods for the manufacture of fluconazole |
WO1996020181A1 (en) * | 1994-12-23 | 1996-07-04 | Acic (Canada) Inc. | Commercial process for the manufacture of fluconazole and intermediates useful in the manufacture thereof |
Non-Patent Citations (4)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 106, No. 9, 02 March 1987, (Columbus, Ohio, USA), page 615, Abstract No. 67325k, MONTSERRAT F.E., "Process for the Preparation of 2-(2,4-Difluorophenyl)-1,3-Bis(1H-1,2,4-Tri azol-1-yl)Propan-2-ol"; & ES,A,549 020. * |
CHEMICAL ABSTRACTS, Vol. 106, No. 9, 02 March 1987, (Columbus, Ohio, USA), page 615, Abstract No. 67326m, MONTSERRAT F.E., "Process for Preparing 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-Tri azol-1-yl)Propan-2-ol"; & ES,A,549 022. * |
CHEMICAL ABSTRACTS, Vol. 119, No. 13, 27 September 1993, (Columbus, Ohio, USA), page 875, Abstract No. 139186j, ZHANG M. et al., "Synthesis and Antifungal Activity of Triazolylpropanol Derivatives"; & ZHEJIANG YIKE DAXUE XUEBAO, 1992, 21(6), 251-5 (Ch). * |
CHEMICAL ABSTRACTS, Vol. 120, No. 21, 23 May 1994, (Columbus, Ohio, USA), page 1054, Abstract No. 270250p, NARAYANAN A. et al., "Conversion of 4-Amino-4H-1,2,4-Triazole to 1,3Bis(1H-Azol-1-yl)-2-Propanols and 1-Phenacyl-4-[(Bezoyl or 4-Toluenesulfonyl)Imino]-(1H-1,2,4-Trizoliu m) Ylides"; & J. HETEROCYCL. CHEM., 1993, * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100341688B1 (en) * | 1999-04-16 | 2002-06-24 | 윤재승 | Process for the Preparation of Fluconazole |
WO2002076955A1 (en) * | 2001-03-23 | 2002-10-03 | Richter Gedeon Vegyeszéti Gyár Rt. | Process for preparing fluconazole and its crystal modifications |
JP2004524348A (en) * | 2001-03-23 | 2004-08-12 | リチュテル・ゲデオン・ヴェジェーセティ・ジャール・エルテー | Method for producing fluconazole and its crystalline deformation |
US7094904B2 (en) | 2001-03-23 | 2006-08-22 | Richter Gedeon Vegyeszeti Gyar Rt. | Process for preparing monohydrate and crystal modifications of fluconazole |
HRP20030854B1 (en) * | 2001-03-23 | 2011-11-30 | Richter Gedeon Vegyesz�ti Gy�r RT | Process for preparing fluconazole and its crystal modifications |
WO2015058272A1 (en) * | 2013-10-23 | 2015-04-30 | Iharabras S.A. Indústrias Químicas | Process for selectively preparing (1h-1,2,4-triazol-1-yl)alkanols, hydrazinyl alkanol compound produced by said process and use thereof |
JP2018533635A (en) * | 2015-11-17 | 2018-11-15 | ダウ アグロサイエンシィズ エルエルシー | 4-((6- (2- (2,4-Difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propyl) pyridine -3-yl) oxy) benzonitrile and method of preparation |
JP2018538366A (en) * | 2015-11-17 | 2018-12-27 | ダウ アグロサイエンシィズ エルエルシー | 4-((6- (2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-yl) propyl) pyridine-3 -Yl) oxy) benzonitrile and preparation method |
CN106749055A (en) * | 2016-12-19 | 2017-05-31 | 苏州天马精细化学品股份有限公司 | A kind of preparation method of Fluconazole |
Also Published As
Publication number | Publication date |
---|---|
EP1001947A1 (en) | 2000-05-24 |
PL329117A1 (en) | 1999-03-15 |
KR100194945B1 (en) | 1999-06-15 |
HUP0000726A2 (en) | 2000-11-28 |
KR19980066917A (en) | 1998-10-15 |
CZ308398A3 (en) | 1999-03-17 |
HUP0000726A3 (en) | 2002-02-28 |
AU5882398A (en) | 1998-08-18 |
SK133298A3 (en) | 1999-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CZ282873B6 (en) | Process for preparing derivatives of n-beta-hydroxyalkyl-tri-n-carboxyalkyl-1,4,7,10-tetraazacyclododecane and n-beta-hydroxyalkyl-tri-n-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane and their metal complexes | |
EP1709005B1 (en) | High purity butoconazole nitrate with specified particle size and a process for preparation thereof | |
EP2563766B1 (en) | Improved process for preparing rufinamide intermediate | |
EP1001947A1 (en) | Process for manufacturing fluconazole | |
US6723798B1 (en) | Resins having vinyl ether linker for the solid phase organic synthesis | |
WO2012032540A1 (en) | Process for preparation of fluorinated triazole compound | |
RU2170736C2 (en) | Method of synthesis of 2-[2,4-difluorophenyl]-1,3-bis-[1h-1,2,4-triazole-1-yl]-propane- 2-ol and its pharmaceutically acceptable salts | |
NO147838B (en) | INTERMEDIATE FOR USE IN PREPARATION OF THE HYPOTENSIVE AGENT 2- (4- (2-FUROYL) PIPERAZIN-1-YL) -4-AMINO-6,7-DIMETOXYKINAZOLINE | |
KR100351743B1 (en) | Process for preparation of the n,n-dicyclohexyl-2-benzothiazole sulfenamide | |
JP2849325B2 (en) | Method for synthesizing 4-halo-5- (hydroxymethyl) imidazole compound | |
EP0611758B1 (en) | Process for synthesizing 4-halo-5(hydroxymethyl) imidazole compounds and certain novel 4-halo-5(hydroxymethyl) imidazole compounds | |
JP3328082B2 (en) | Process for producing N-guanidinothiourea salt and 3-amino-5-mercapto-1,2,4-triazole | |
JP3468543B2 (en) | 2-butyl-4-chloro-5-methylimidazole and method for synthesizing the same | |
KR100448640B1 (en) | Method for producing phenyl propionic acid derivatives with high yield and purity | |
KR100341688B1 (en) | Process for the Preparation of Fluconazole | |
CN116768807A (en) | Preparation method of 3- (chloromethyl) -1-methyl-1H-1, 2, 4-triazole hydrochloride | |
RU2231526C2 (en) | Method for preparing 3,5-diamino-6-(2,3-dichloro)-1,2,4-triazine | |
KR100327818B1 (en) | Process for the Preparation of Fluconazole | |
JPH0469156B2 (en) | ||
WO1999025715A1 (en) | Preparation of terazosin hydrochloride dihydrate | |
JPS62286977A (en) | Manufacture of azole derivatives | |
JP2000297078A (en) | Production of metal salt of tetrazole compound | |
JPH0616628A (en) | Indole derivative | |
HU187289B (en) | Process for preparing 4-//2-amino-ethyl/-thiomethyl/-5-methyl-imidazole | |
KR19980067686A (en) | Method for preparing triazole derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 133298 Country of ref document: SK Ref document number: PV1998-3083 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998902274 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: PV1998-3083 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998902274 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998902274 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: PV1998-3083 Country of ref document: CZ |